Evidence map›Paper›PMID 36917949›Full record

ReviewCancer cell2023

Activated fibroblasts in cancer: Perspectives and challenges.

Giuseppina Caligiuri, David A Tuveson

Abstract readReview
In one paragraph

Review in Cancer cell, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 283 papers.

0numbers the graph read from it
0cells of the map it votes in
283citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

283 citing papers in PubMed.

  1. Trial
  2. Trial
  3. Article
  4. Article
  5. Review
  6. Article
  7. SDC1Gut · 2026
    Article
  8. Article
  9. Article
  10. Article
  11. Observational
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Review
  18. Article
  19. Review
  20. Article

223 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Giuseppina CaligiuriCold Spring Harbor Laboratory, Cold Spring Harbor, NY, USA; Lustgarten Foundation Pancreatic Cancer Research Laboratory, Cold Spring Harbor, NY, USA.
David A TuvesonCold Spring Harbor Laboratory, Cold Spring Harbor, NY, USA; Lustgarten Foundation Pancreatic Cancer Research Laboratory, Cold Spring Harbor, NY, USA. Electronic address: dtuveson@cshl.edu.

Funding

Single-Cell Biology Shared ResourceP30CA045508 · NCI · COLD SPRING HARBOR LABORATORY · PI John Edward Moses · 1987 to 2026
$118.9M
Pancreatic Cancer Detection ConsortiumU01CA210240 · NCI · UNIVERSITY OF NEBRASKA MEDICAL CENTER · PI Michael A. Hollingsworth · 2017 to 2026
$12.9M
CSHL-JAX Patient-Derived Models of Pancreatic Cancer as Systems for Investigating Tumor HeterogeneityU01CA224013 · NCI · COLD SPRING HARBOR LABORATORY · PI ROBSON, PAUL, TUVESON, DAVID A · 2018 to 2022
$4.2M
Fibroblast Heterogeneity in Pancreatic CancerR01CA249002 · NCI · COLD SPRING HARBOR LABORATORY · PI TUVESON, DAVID A · 2021 to 2025
$3.9M
Targeting aberrant enhancer landscapes in pancreatic cancerR01CA229699 · NCI · ST. JUDE CHILDREN'S RESEARCH HOSPITAL · PI Christopher Vakoc · 2019 to 2026
$3.3M
Nrf2 Regulation of Ductal Pancreatic Cancer Etiology and Treatment ResponseR01CA188134 · NCI · COLD SPRING HARBOR LABORATORY · PI TUVESON, DAVID A · 2017 to 2021
$3.0M
(PQA-4) Organoid Omics To Detect And Defeat Ductal Pancreatic CancerR01CA190092 · NCI · COLD SPRING HARBOR LABORATORY · PI TUVESON, DAVID A · 2014 to 2017
$2.2M
NCI NIH HHS P30 CA045508NCI NIH HHS R01 CA188134NCI NIH HHS R01 CA190092NCI NIH HHS R01 CA229699NCI NIH HHS R01 CA249002NCI NIH HHS U01 CA210240NCI NIH HHS U01 CA224013
6 · The paper itself

Abstract

Activated fibroblasts in tumors, or cancer-associated fibroblasts (CAFs), have become a popular research area over the past decade. As important players in many aspects of tumor biology, with functions ranging from collagen deposition to immunosuppression, CAFs have been the target of clinical and pre-clinical studies that have revealed their potential pro- and anti-tumorigenic dichotomy. In this review, we describe the important role of CAFs in the tumor microenvironment and the technological advances that made these discoveries possible, and we detail the models that are currently available for CAF investigation. Additionally, we present evidence to support the value of encompassing CAF investigation as a future therapeutic avenue alongside immune and cancer cells while highlighting the challenges that must be addressed for successful clinical translation of new findings.

Indexed as

Cancer-Associated FibroblastsNeoplasmsCarcinogenesisFibroblastsHumansImmune ToleranceTumor Microenvironmentactivated fibroblastscancer-associated fibroblastsstromatumor microenvironment

Identifiers

PMID36917949
PMCPMC11022589

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.